{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:57:47Z","timestamp":1782917867982,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007797","name":"Helsingin Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"iCAN Digital Precision Cancer Medicine Flagship"},{"DOI":"10.13039\/501100007083","name":"Orionin Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007634","name":"Ida Montinin S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003756","name":"Biomedicum Helsinki-s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The utility of circulating tumor DNA (ctDNA) for mutational genotyping, pretreatment prognostication, and assessment of molecular response is well established in patients with aggressive large B-cell lymphoma (LBCL). Here, we have applied targeted panel and duplex sequencing of plasma ctDNA to study copy number aberrations (CNAs) along with mutational landscapes in 123 uniformly treated patients with high-risk LBCL. We find a robust correlation between targeted and whole-genome sequenced CNA landscapes (\n                    <jats:italic>R<\/jats:italic>\n                    \u2009=\u20090.81) and identify CNAs in the ctDNA in 76% of the patients above the limit of detection. We describe the most frequently affected genomic regions, their interactions with diagnostic and genetic subtypes, and associations with overall and progression-free survival. Specifically, we show how ctDNA profiling of\n                    <jats:italic>TP53<\/jats:italic>\n                    loss outperforms fluorescence in situ hybridization (FISH)-based\n                    <jats:italic>TP53<\/jats:italic>\n                    \/17p analysis in risk assessment, independent of clinical risk factors and ctDNA concentration. We validate key findings of prognostic tumor fraction and\n                    <jats:italic>TP53<\/jats:italic>\n                    loss in an independent LBCL cohort. Furthermore, we detect dynamic shifts between the fractions of lymphoma clones by assessing CNAs and mutations in the ctDNA at disease progression. These findings demonstrate the potential of minimally invasive, targeted CNA analysis in resolving the molecular heterogeneity of LBCLs.\n                  <\/jats:p>","DOI":"10.1038\/s41375-026-02955-w","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:53:41Z","timestamp":1776844421000},"page":"1381-1391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1837-1587","authenticated-orcid":false,"given":"Maare","family":"Arffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Meriranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Liisa","family":"Karjalainen-Lindsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Beiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Drott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Fluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirkku","family":"Jyrkki\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6522-4086","authenticated-orcid":false,"given":"Peter","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-9428","authenticated-orcid":false,"given":"Harald","family":"Holte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-511X","authenticated-orcid":false,"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"2955_CR1","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140:1229\u201353.","journal-title":"Blood"},{"key":"2955_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"2955_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384:842\u201358.","journal-title":"N Engl J Med"},{"key":"2955_CR4","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1200\/JCO.18.01994","volume":"37","author":"NL Bartlett","year":"2019","unstructured":"Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303. J Clin Oncol. 2019;37:1790\u20139.","journal-title":"J Clin Oncol"},{"key":"2955_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"2955_CR6","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"2955_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551\u201368.","journal-title":"Cancer Cell"},{"key":"2955_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"2955_CR9","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","volume":"39","author":"CB Steen","year":"2021","unstructured":"Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell. 2021;39:1422\u201337.","journal-title":"Cancer Cell"},{"key":"2955_CR10","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","volume":"11","author":"N Kotlov","year":"2021","unstructured":"Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z, et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 2021;11:1468\u201389.","journal-title":"Cancer Discov"},{"key":"2955_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.medj.2024.03.007","volume":"5","author":"M Arffman","year":"2024","unstructured":"Arffman M, Meriranta L, Autio M, Holte H, Jorgensen J, Brown P, et al. Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas. Med. 2024;5:583\u2013602 e5.","journal-title":"Med"},{"key":"2955_CR12","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report. Blood. 2020;135:1759\u201371.","journal-title":"Blood"},{"key":"2955_CR13","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1182\/blood.V87.12.5269.bloodjournal87125269","volume":"87","author":"O Monni","year":"1996","unstructured":"Monni O, Joensuu H, Franssila K, Knuutila S. DNA copy number changes in diffuse large B-cell lymphoma\u2013comparative genomic hybridization study. Blood. 1996;87:5269\u201378.","journal-title":"Blood"},{"key":"2955_CR14","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1182\/blood-2005-04-1399","volume":"106","author":"S Bea","year":"2005","unstructured":"Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106:3183\u201390.","journal-title":"Blood"},{"key":"2955_CR15","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2018889931","volume":"133","author":"M Pascual","year":"2019","unstructured":"Pascual M, Mena-Varas M, Robles EF, Garcia-Barchino MJ, Panizo C, Hervas-Stubbs S, et al. PD-1\/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood. 2019;133:2401\u201312.","journal-title":"Blood"},{"key":"2955_CR16","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3109\/10428194.2014.970550","volume":"56","author":"I Fiskvik","year":"2015","unstructured":"Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, et al. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56:1742\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2955_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70139","volume":"9","author":"S Leppa","year":"2025","unstructured":"Leppa S, Meriranta L, Arffman M, Jorgensen J, Karjalainen-Lindsberg ML, Beiske K, et al. Biomarker-adapted treatment in high-risk large B-cell lymphoma. Hemasphere. 2025;9:e70139.","journal-title":"Hemasphere"},{"key":"2955_CR18","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O\u2019Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268\u201377.","journal-title":"Blood"},{"key":"2955_CR19","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2009-10-247122","volume":"116","author":"F Jardin","year":"2010","unstructured":"Jardin F, Jais JP, Molina TJ, Parmentier F, Picquenot JM, Ruminy P, et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. Blood. 2010;116:1092\u2013104.","journal-title":"Blood"},{"key":"2955_CR20","doi-asserted-by":"publisher","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","volume":"8","author":"F Scherer","year":"2016","unstructured":"Scherer F, Kurtz DM, Newman AM, Stehr H, Craig AF, Esfahani MS, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8:364ra155.","journal-title":"Sci Transl Med"},{"key":"2955_CR21","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood.2021012852","volume":"139","author":"L Meriranta","year":"2022","unstructured":"Meriranta L, Alkodsi A, Pasanen A, Lepisto M, Mapar P, Blaker YN, et al. Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 2022;139:1863\u201377.","journal-title":"Blood"},{"key":"2955_CR22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41587-022-01222-4","volume":"40","author":"MS Esfahani","year":"2022","unstructured":"Esfahani MS, Hamilton EG, Mehrmohamadi M, Nabet BY, Alig SK, King DA, et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nat Biotechnol. 2022;40:585\u201397.","journal-title":"Nat Biotechnol"},{"key":"2955_CR23","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39:1537\u201347.","journal-title":"Nat Biotechnol"},{"key":"2955_CR24","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","volume":"36","author":"DM Kurtz","year":"2018","unstructured":"Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J Clin Oncol. 2018;36:2845\u201353.","journal-title":"J Clin Oncol"},{"key":"2955_CR25","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1200\/JCO.20.02573","volume":"39","author":"S Alig","year":"2021","unstructured":"Alig S, Macaulay CW, Kurtz DM, Duhrsen U, Huttmann A, Schmitz C, et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma. J Clin Oncol. 2021;39:2605\u201316.","journal-title":"J Clin Oncol"},{"key":"2955_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1158\/1078-0432.CCR-20-2558","volume":"27","author":"A Rivas-Delgado","year":"2021","unstructured":"Rivas-Delgado A, Nadeu F, Enjuanes A, Casanueva-Eliceiry S, Mozas P, Magnano L, et al. Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study. Clin Cancer Res. 2021;27:513\u201321.","journal-title":"Clin Cancer Res"},{"key":"2955_CR27","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548\u201354.","journal-title":"Nat Med"},{"key":"2955_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nbt.3520","volume":"34","author":"AM Newman","year":"2016","unstructured":"Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:547\u201355.","journal-title":"Nat Biotechnol"},{"key":"2955_CR29","doi-asserted-by":"crossref","unstructured":"Roschewski M, Kurtz DM, Westin JR, Lynch RC, Gopal AK, Alig SK, et al. Remission assessment by circulating tumor DNA in large B-cell lymphoma. J Clin Oncol. 2025;43:3652\u201361.","DOI":"10.1200\/JCO-25-01534"},{"key":"2955_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3324\/haematol.2020.268813","volume":"107","author":"L Raman","year":"2022","unstructured":"Raman L, Van der Linden M, De Vriendt C, Van den Broeck B, Muylle K, Deeren D, et al. Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: a standardized approach with underappreciated potential. Haematologica. 2022;107:211\u201320.","journal-title":"Haematologica"},{"key":"2955_CR31","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/bloodadvances.2024014136","volume":"9","author":"R Moia","year":"2025","unstructured":"Moia R, Talotta D, Terzi Di Bergamo L, Almasri M, Dondolin R, Salehi M, et al. Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels. Blood Adv. 2025;9:1692\u2013701.","journal-title":"Blood Adv"},{"key":"2955_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","volume":"41","author":"BJ Sworder","year":"2023","unstructured":"Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell. 2023;41:210\u201325.","journal-title":"Cancer Cell"},{"key":"2955_CR33","doi-asserted-by":"crossref","unstructured":"Meriranta L, Rask Kragh Jorgensen R, Pasanen A, Kolstad A, Hutchings M, Niemann CU, et al. Circulating tumor DNA determinants of response and outcome in relapsed\/refractory mantle cell lymphoma. Blood Adv. 2025;9:4528\u201341.","DOI":"10.1182\/bloodadvances.2025015791"},{"key":"2955_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"Adalsteinsson","year":"2017","unstructured":"Adalsteinsson, Ha VA, Freeman G, Choudhury SS, Stover AD, Parsons HA DG, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324.","journal-title":"Nat Commun"},{"key":"2955_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/gm434","volume":"5","author":"E Heitzer","year":"2013","unstructured":"Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, et al. Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 2013;5:30.","journal-title":"Genome Med"},{"key":"2955_CR36","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/jnci\/djad080","volume":"115","author":"MH Kim","year":"2023","unstructured":"Kim MH, Kim GM, Ahn JM, Ryu WJ, Kim SG, Kim JH, et al. Copy number aberrations in circulating tumor DNA enables prognosis prediction and molecular characterization of breast cancer. J Natl Cancer Inst. 2023;115:1036\u201349.","journal-title":"J Natl Cancer Inst"},{"key":"2955_CR37","doi-asserted-by":"crossref","unstructured":"Wang N, Tao ZY, Wu T, Wang J, Wang W, Shi H, et al. Benchmarking copy number variation detection with low-coverage whole-genome sequencing. Brief Bioinform. 2025;26:514.","DOI":"10.1093\/bib\/bbaf514"},{"key":"2955_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115630","volume":"168","author":"MTN Nguyen","year":"2023","unstructured":"Nguyen MTN, Rajavuori A, Huhtinen K, Hietanen S, Hynninen J, Oikkonen J, et al. Circulating tumor DNA-based copy-number profiles enable monitoring treatment effects during therapy in high-grade serous carcinoma. Biomed Pharmacother. 2023;168:115630.","journal-title":"Biomed Pharmacother"},{"key":"2955_CR39","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2024025652","volume":"145","author":"B Chapuy","year":"2025","unstructured":"Chapuy B, Wood T, Stewart C, Dunford A, Wienand K, Khan SJ, et al. DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in DLBCL. Blood. 2025;145:2041\u201355.","journal-title":"Blood"},{"key":"2955_CR40","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1182\/bloodadvances.2020001518","volume":"4","author":"S Leppa","year":"2020","unstructured":"Leppa S, Jorgensen J, Tierens A, Meriranta L, Ostlie I, de Nully Brown P, et al. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv. 2020;4:1906\u201315.","journal-title":"Blood Adv"},{"key":"2955_CR41","doi-asserted-by":"crossref","unstructured":"Krupka JA, Moutsopoulos I, Cutmore NH, Trethewey CS, Dayimu A, Goodhew R, et al. The DIRECT study: a roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in diffuse large B cell lymphoma. medRxiv. 2025:2025.04.14.25325806.","DOI":"10.1101\/2025.04.14.25325806"},{"key":"2955_CR42","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:D980\u20135.","journal-title":"Nucleic Acids Res"},{"key":"2955_CR43","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nmeth.2883","volume":"11","author":"A Roth","year":"2014","unstructured":"Roth A, Khattra J, Yap D, Wan A, Laks E, Biele J, et al. PyClone: statistical inference of clonal population structure in cancer. Nat Methods. 2014;11:396\u20138.","journal-title":"Nat Methods"},{"key":"2955_CR44","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1038\/s41375-022-01618-w","volume":"36","author":"EM Lauer","year":"2022","unstructured":"Lauer EM, Mutter J, Scherer F. Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. Leukemia. 2022;36:2151\u201364.","journal-title":"Leukemia"},{"key":"2955_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.584","volume":"11","author":"MC Zhang","year":"2021","unstructured":"Zhang MC, Fang Y, Xu PP, Dong L, Shen R, Huang YH, et al. Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1\/2 and biomarker study. Clin Transl Med. 2021;11:e584.","journal-title":"Clin Transl Med"},{"key":"2955_CR46","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","volume":"41","author":"MC Zhang","year":"2023","unstructured":"Zhang MC, Tian S, Fu D, Wang L, Cheng S, Yi HM, et al. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: the randomized GUIDANCE-01 trial. Cancer Cell. 2023;41:1705\u201316.","journal-title":"Cancer Cell"},{"key":"2955_CR47","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","volume":"375","author":"JS Welch","year":"2016","unstructured":"Welch JS, Petti AA, Miller CA, Fronick CC, O\u2019Laughlin M, Fulton RS, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023\u201336.","journal-title":"N Engl J Med"},{"key":"2955_CR48","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1182\/bloodadvances.2020003039","volume":"5","author":"L Buedts","year":"2021","unstructured":"Buedts L, Wlodarska I, Finalet-Ferreiro J, Gheysens O, Dehaspe L, Tousseyn T, et al. The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA. Blood Adv. 2021;5:1991\u20132002.","journal-title":"Blood Adv"},{"key":"2955_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0111-6","volume":"8","author":"E Bohers","year":"2018","unstructured":"Bohers E, Viailly PJ, Becker S, Marchand V, Ruminy P, Maingonnat C, et al. Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. Blood Cancer J. 2018;8:74.","journal-title":"Blood Cancer J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02955-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02955-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02955-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:39:46Z","timestamp":1782916786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02955-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2955"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02955-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.J*: AbbVie: Consultancy; BMS: Consultancy; Caribou Bioscience: Consultancy; Gilead: Consultancy; Incyte: Consultancy; Novartis: Consultancy; Roche: Consultancy. Sobi: Consultancy. K.D*: AbbVie: Honoraria, Roche: Honoraria, Respiratorius: Honoraria, Incyte: Advisory board. P.B*: BMS: Consultancy; Roche: Consultancy, Novartis: Consultancy H.H*: Genmab: Safety Committee; Incyte: Consultancy; Novartis: Research Funding; Elicera Therapeutics: Safety Committee; Serb SA: Advisory Board S.L*: AbbVie: Honoraria, Consultation; AstraZeneca: Consultation; GENMAB: Research Funding**;GILEAD: Honoraria; Incyte, Consultation, Honoraria; Novartis: Research Funding*; Roche: Honoraria, Consultancy, Research Funding*; BMS\/Celgene: Consultancy, Research Funding**. Other authors declare no conflicts of interest. *All outside of the submitted work. **To the institute.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Part of the work has been presented at the AACR Annual Meeting 2025.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}}]}}